DGAP-News: PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS
Retrieved on:
Wednesday, September 1, 2021
Sepsis, Philippe Ciais, Hypotension, Royal commission, Abscess, Anesthesia, Angiotensin, Peritonitis, Product, Meropenem, AG, Infectious Diseases Society of America, Intra-abdominal infection, Abdominal cavity, IDSA, Carbapenem, Infection, European Medicines Agency, Ertapenem, Aachen, Remimazolam, EU, ICU, PA8, Shock, ISIN, Catecholamine, Patient, Septic, European Commission, Multiplicity of infection, Tetracycline, Critical care, Frankfurt Stock Exchange, Health, Antibiotics, Pharmaceutical industry, complicated intra-abdominal infections (cIAI), XERAVA(R) (eravacycline), PAION, COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), XERAVA(R) (ERAVACYCLINE), PAION
XERAVA(R) is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
Key Points:
- XERAVA(R) is approved by the European Commission and the UK Medicines Agency for the treatment of complicated intra-abdominal infections (cIAI) in adults.
- XERAVA(R) is a fluorocycline antibiotic within the tetracycline class of antibacterial drugs and provides broad-spectrum coverage against different bacterial pathogens responsible for complicated intra-abdominal infections (cIAI).
- Dr. Jim Phillips, Chief Executive Officer of PAION AG, stated: "XERAVA is an important new treatment option for patients suffering from serious intra-abdominal infections.
- XERAVA(R) is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.